share_log

东吴证券4月21日发布研报称，给予昆药集团（600422.SH）买入评级。评级理由主要包括：1）“昆中药1381”品牌造势初见成效，三大黄金单品表现亮眼；2）“777”品牌正式推出,三七全产业链高质量发展持续推进。（每日经济新闻）

Dongwu Securities released a research report on April 21 stating that it gave KPC Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) the “Kunming Traditional Chinese Medicine 1381” brand has seen initial results, and the thre

Zhitong Finance ·  Apr 21 12:13
Dongwu Securities released a research report on April 21 stating that it gave KPC Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) the “Kunming Traditional Chinese Medicine 1381” brand has seen initial results, and the three major gold products have performed brilliantly; 2) the “777” brand was officially launched, and the high-quality development of the entire 37 industry chain continues to advance. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment